The pharmacological properties of two NK1 antagonists were studied in comparison with a benzodiazepine during a 7% CO2 challenge in a population of healthy volunteers selected for a high sensitivity to the challenge. In total, 19 healthy subjects, pre-screened for their responsiveness to the 7% CO2 test, took part in the randomised, double-blind, cross-over, incomplete block design study. After receiving treatment or placebo, the volunteers were subjected to three 7% CO2 challenges each for a time of 20 min. The treatment consisted of the administration of the following three active drugs: a single dose of benzodiazepine alprazolam (0.75 mg) and a single dose of the NK1 antagonists vestipitant (GW597599) (15 mg) and vofopitant (GR205171) (25 mg). Anxiety during the challenge was evaluated with Visual Analogue Scale-Anxiety (VAS-A) and with Panic Symptom List (PSL III-R). Respiratory parameters, heart rate and skin conductance were also recorded. Compared with placebo, vestipitant showed a significant reduction (p<0.05) in anxiety assessed on the VAS-A scale (ΔVAS-A%) while alprazolam significantly (p<0.01) attenuated the PSL III-R total score. Vofopitant did not show any anxiolytic effect. In the comparison analysis between placebo and drugs, none of the respiratory and other physiological parameters showed a statistically significant difference.
ArgyropoulosSVBaileyJEHoodSD. (2002) Inhalation of 35% CO2 results in activation of the HPA axis in healthy volunteers. Psychoneuroendocrinology27: 715–729.
2.
BaileyJEArgyropoulosSVKendrickA. (2005) Behavioral and cardiovascular effects of 7.5% CO2 in human volunteers. Depress Anxiety21: 18–25.
3.
BaileyJEKendrickADiaperA. (2007) A validation of 7.5% CO2 model of GAD using paroxetine and lorazepam in healthy volunteers. J Psychopharmacol21: 42–49.
4.
BaileyJEPapadopoulosADiaperA. (2011a) Preliminary evidence of anxiolytic effects of the CRF1 receptor antagonist R317573 in the 7.5% CO2 proof-of-concept experimental model of human anxiety. J Psychopharmacol25: 1199–1206.
5.
BaileyJEDawsonGRDourishCT. (2011b) Validating the inhalation of 7.5% CO(2) in healthy volunteers as a human experimental medicine: A model of generalized anxiety disorder (GAD). J Psychopharmacol25: 1192–1198.
6.
BattagliaMPernaG (1995) The 35% CO2 challenge in panic disorder: Optimization by receiver operating characteristic (ROC) analysis. J Psychiat Res29: 111–119.
7.
BrambillaFPeriniGSerraM. (2013) Changes in neuroactive steroid secretion associated with CO2-induced panic attacks in normal individuals. Psychoneuroendocrinology. 38: 2234–2242.
8.
CaldirolaDBellodiLCaumoA. (2004a) Approximate entropy of respiratory patterns in panic disorder. Am J Psychiatry161: 79–87.
9.
CaldirolaDBellodiLCamminoS. (2004b) Smoking and respiratory irregularity in panic disorder. Biol Psychiatry56: 393–398.
10.
ChamblessDLCaputoGCBrightP. (1984) Assessment of fear of fear in agoraphobics: The Body Sensations Questionnaire and the Agoraphobic Cognitions Questionnaire. J Cons Clin Psychol52: 1090.
11.
CoryellWPineDFyerA. (2006) Anxiety responses to CO2 inhalation in subjects at high-risk for panic disorder. J Affect Disord92: 63–70.
12.
EbnerKSartoriSBSingewaldN (2009) Tachykinin receptors as therapeutic targets in stress-related disorders. Curr Pharm Des15: 1647–1674.
13.
EMEA European Medicines Agency (2003) Note for guidance on clinical investigations of medicinal products indicated for the treatment of Panic Disorders. London: CHMP-EMEA.
14.
ForsythJPEifertGHCannaMA (2000) Evoking analogue subtypes of panic attacks in a nonclinical population using carbon dioxide-enriched air. Behav Res Ther38: 559–572.
15.
FurmarkTAppelLMichelgårdA. (2005) Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry58: 132–142.
16.
GormanJMBrowneSTPappLA. (1997) Effect of antipanic treatment on response to carbon dioxide. Biol Psychiatry42: 982–991.
17.
HalaszJTothMMikicsE. (2008) The effect of eurokinin1 receptor blockade on territorial aggression and in a model of violent aggression. Biol Psychiatry63: 271–278.
18.
HeldtSADavisMRattiE. (2009) Anxiolytic-like effects of the neurokinin 1 receptor antagonist GR-205171 in the elevated plus maze and contextual fear-potentiated startle model of anxiety in gerbils. J Behav Pharmacol20: 584–595.
19.
KellerMMontgomerySBallW. (2006) Lack of efficacy of the substance-P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry59: 216–223.
20.
KleinDF (1993) False suffocation alarms, spontaneous panics and related conditions: An integrative hypothesis. Arch Gen Psychiatry50:306–317.
21.
KramerMSCutlerNFeighnerJ (1998) Distinct mechanism for antidepressant activity by blockage of central Substance P receptors. Science281: 1640–1645.
22.
MalkesmanOBrawYWellerA (2007) Assessment of antidepressant and anxiolytic properties of NK1 antagonists and substance P in Wistar Kyoto rats. Physiol Behav16: 619–625.
23.
MathewSJVythilingamMMurroughJW. (2011) A selective neurokinin-1 receptor antagonist in chronic PTSD: A randomized, double-blind, placebo-controlled, proof-of-concept trial. Eur Neuropsychopharmacol21: 221–229.
24.
McLeanS (2005) Do substance P and NK1 receptor have a role in depression and anxiety?Curr Pharm Des11: 1529–1547.
25.
PapadopoulosARichANuttDJ. (2010) The effects of single dose anxiolytic medication on the CO2 models of anxiety: Differentiation of subjective and objective measures. J Psychopharmacol24: 649–656.
26.
PernaGBertaniACaldirolaD. (2002) Antipanic drug modulation of 35% CO2 hyperreactivity and short-term treatment outcome. J Clin Psychopharmacol22: 300–308.
27.
RattiEBellewKBetticaP. (2011) Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder. J Clin Psychopharmacol31: 727–733.
28.
SchruersKEsquivelGvan DuinenM. (2011) Genetic moderation of CO2-induced fear by 5-HTTLPR genotype. J Psychopharmacol25: 37–42.
29.
SeddonKMorrisKBaileyJ. (2011) Effects of 7.5% CO2 challenge in generalized anxiety disorder. J Psychopharmacol25: 43–51.
30.
SheehanDVLecrubierY (1994) Mini International Neuropsychiatric Interview (M.I.N.I.). Tampa, FL: University of South Florida Institute for Research in Psychiatry.
31.
SpielbergerCD (1983) Manual for the State-Trait Anxiety Inventory, revised edition. Palo Alto, CA: Consulting Psychologists Press.
32.
WoodsSWKrystalJHHeningerGR. (1989) Effects of alprazolam and clonidine on carbon dioxide-induced increases in anxiety ratings in healthy human subjects. Life Sci45: 233–242.
33.
Zanone PomaSMilleriSSquassanteL. (2005) Characterization of a 7% carbon dioxide (CO2) inhalation paradigm to evoke anxiety symptoms in healthy subjects. J Psychopharmachol19: 494–503.
